Non Small Cell Lung Cancer Clinical Trial
Official title:
A Study of Reducing the Symptom Burden Produced by Chemoradiation Treatment for Non Small Cell Lung Cancer
The goal of this clinical research study is to compare armodafinil, bupropion, curcumin, and minocycline when given alone or in combination to learn which is better for controlling symptoms, such as the side effects of chemoradiation, when given to treat lung cancer.
The Study Drugs:
It is not known which study drug or combination of study drugs is better at reducing side
effects patients may experience during chemoradiation therapy. For this reason, researchers
have chosen 4 study drugs that may help to reduce side effects. The study drugs will be
tested alone and in combination with each other.
Armodafinil is designed to prevent excessive sleepiness.
Bupropion is an antidepressant with anti-inflammatory properties that may help reduce
multiple symptoms.
Curcumin is the active ingredient in the spice, turmeric. It may interfere with the
production of cytokines (which cause inflammation), which may reduce multiple symptoms.
Minocycline is an antibiotic. Minocycline has been shown to interrupt cytokine production,
which may help to reduce multiple symptoms.
Study Groups:
If you agree to take part in this study, you will be randomly assigned (as in the roll of
dice) to join 1 of 16 groups. You may be assigned to receive no study drugs, 1 study drug,
or a combination of 2, 3, or all 4 of the study drugs.
During this study, you may receive 1 or more placebos. A placebo looks like the study
drug(s) but has no active ingredients. There is a chance that you will be in a group that
does not receive any study drugs at all. However, all patients are under standard care by
their treating doctors.
Neither you nor the study staff you will see in the clinic will know if you are receiving
the study drugs and/or the placebo(s). However, if needed for your safety, the study staff
will be able to find out which study drug you are receiving.
Study Drug Administration:
You will take the study drugs/placebos every day for 10 weeks. You will take either single
or combined study drug(s) or placebos by mouth everyday as instructed by the study doctor.
You will be given pamphlets with more information about how to take the study
drugs/placebos.
You will be given a daily diary to write down when you take the study drugs/placebo. You
should bring your study drug/placebo blister packs/sticks to the clinic to every study
visit. You should also bring your diary to every visit.
Completing the Symptom Questionnaire:
Throughout the study, you will be asked to complete the symptom questionnaire. You will be
asked about symptoms from therapy you may be experiencing and how they may be interfering
with your daily activities. The study staff will either meet you during your regular clinic
visit or call you at your home at a time that is convenient for you. In the clinic, you will
complete the questionnaire by paper and pen, or by entering your answers into an electronic
tablet computer. On the phone, study staff will ask you the questions and record your
answers on paper or enter them into a computer. The symptom questionnaire will take up to 5
minutes to complete.
- During Weeks 1-10, you will complete the symptom questionnaire 2 times a week.
- During Weeks 11-16, you will complete the symptom questionnaire 1 time a week.
Study Visits:
Before you begin chemoradiation:
- You will complete 4 questionnaires about pain and other symptoms, your mood, and your
quality of life. Completing all 4 of the questionnaires will take about 15 minutes.
- You will have a blood coagulation test, called a PT-INR, to make sure your blood clots
normally.
- If you are a woman who is able to become pregnant, you will have a urine pregnancy
test. The study staff will give you the pregnancy test kit at your scheduled visit, and
will review and record the results of the test before your study prescriptions are
filled by the pharmacy.
After 4 weeks of chemoradiation:
- You will complete 1 questionnaire about your quality of life. This questionnaire will
take about 2-3 minutes to complete.
- You will have a blood coagulation test, called a PT-INR, to make sure your blood clots
normally.
During the last week of chemoradiation (about Week 7):
-You will complete 3 questionnaires about your symptoms, mood, and quality of life. These
questionnaires will take about 10 minutes total to complete.
After about Week 7, the study staff will call you 2 times a week to check on you until week
10. This phone call should last only a few minutes. If you have experienced several side
effects from chemoradiation, this phone call make take longer.
About Week 12 (at a routine clinical visit):
- You will complete 3 questionnaires about your symptoms, mood, and quality of life.
- If you were smoking at the beginning of the study, you will complete a questionnaire
that asks if you stopped smoking any time during the study. This will take a few
minutes.
- You will have a blood coagulation test, called a PT-INR, to make sure your blood clots
normally.
- You will be asked to complete another questionnaire that asks about your satisfaction
with the study drug(s). This will take a few minutes.
Length of Study:
You will be on study for about 16 weeks. You will take the study drug(s) for 10 weeks and
complete the symptom survey until 16 weeks. You will be taken off study if you experience
intolerable side effects.
This is an investigational study. Armodafinil is FDA approved and commercially available for
the treatment of excessive sleepiness. Bupropion is FDA approved and commercially available
for the treatment of depression. Minocycline is FDA approved and commercially available for
the treatment of bacterial infection. Curcumin is not FDA approved. At this time, curcumin
is only being used in research. The different possible combinations of these drugs being
used in this study is investigational.
Up to 32 patients will take part in this study. All will be enrolled at MD Anderson.
;
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Supportive Care
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05094804 -
A Study of OR2805, a Monoclonal Antibody Targeting CD163, Alone and in Combination With Anticancer Agents
|
Phase 1/Phase 2 | |
Recruiting |
NCT05707286 -
Pilot Study to Determine Pro-Inflammatory Cytokine Kinetics During Immune Checkpoint Inhibitor Therapy
|
||
Recruiting |
NCT04258137 -
Circulating DNA to Improve Outcome of Oncology PatiEnt. A Randomized Study
|
N/A | |
Completed |
NCT01945021 -
Phase II Safety and Efficacy Study of Crizotinib in East Asian Patients With ROS1 Positive, ALK Negative Advanced NSCLC
|
Phase 2 | |
Completed |
NCT04487457 -
Prospective Study to Evaluate the Blood Kinetics of Immune Cells and Immunosuppressive Cytokines After Exposure to an Immunity Checkpoint Inhibitor (ICI): Study of the Impact of Chemotherapy
|
||
Terminated |
NCT04022876 -
A Study of ALRN-6924 for the Prevention of Chemotherapy-induced Side Effects (Chemoprotection)
|
Phase 1 | |
Recruiting |
NCT05898763 -
TEIPP Immunotherapy in Patients With NSCLC
|
Phase 1/Phase 2 | |
Recruiting |
NCT05532696 -
Phase 1b/2 Study to Evaluate ABT-101 in Solid Tumor and NSCLC Patients
|
Phase 1/Phase 2 | |
Completed |
NCT04311034 -
A Study of RC48-ADC in Subjects With Advanced Non-small Cell Lung Cancer
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT03177291 -
Pirfenidone Combined With Standard First-Line Chemotherapy in Advanced-Stage Lung NSCLC
|
Phase 1 | |
Terminated |
NCT03257722 -
Pembrolizumab + Idelalisib for Lung Cancer Study
|
Phase 1/Phase 2 | |
Completed |
NCT00349089 -
Trial on Refinement of Early Stage Lung Cancer Adjuvant Therapy
|
Phase 2 | |
Completed |
NCT05116891 -
A Phase 1/2 Study of CAN04 in Combination With Different Chemotherapy Regimens in Subjects With Advanced Solid Tumors
|
Phase 1/Phase 2 | |
Recruiting |
NCT04571632 -
Clinical Trial of SBRT and Systemic Pembrolizumab With or Without Avelumab/Ipilimumab+ Dendritic Cells in Solid Tumors
|
Phase 2 | |
Terminated |
NCT03599518 -
DS-1205c With Gefitinib for Metastatic or Unresectable Epidermal Growth Factor Receptor (EGFR)-Mutant Non-Small Cell Lung Cancer
|
Phase 1 | |
Not yet recruiting |
NCT06020989 -
Lazertinib and Chemotherapy Combination in EGFR-mutant NSCLC Patients Without ctDNA Clearance After lead-in Lazertinib Monotherapy
|
Phase 2 | |
Withdrawn |
NCT03982134 -
PDR001 + Panobinostat for Melanoma and NSCLC
|
Phase 1 | |
Withdrawn |
NCT03574649 -
QUILT-2.024: Phase 2 Neoadjuvant, Consolidation, and Adjuvant Combination NANT Immunotherapy Versus Standard of Care in Subjects With Resectable Non-small Cell Lung Cancer
|
Phase 2 | |
Withdrawn |
NCT02844140 -
DE-CT in Lung Cancer Proton Therapy
|
N/A | |
Completed |
NCT03780010 -
Study of TRC105 + Paclitaxel/Carboplatin and Bevacizumab in Patients With NSCLC
|
Phase 1 |